AIM ImmunoTech 将来の成長

Future 基準チェック /26

AIM ImmunoTechの収益は年間0.3%で減少すると予測されていますが、年間収益は年間74.5%で増加すると予想されています。EPS は年間8.1%で増加すると予想されています。

主要情報

-0.3%

収益成長率

8.1%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	74.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	22 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:HXB2 - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	8	-32	N/A	N/A	1
12/31/2025	3	-24	N/A	-6	2
12/31/2024	0	-20	N/A	-8	2
9/30/2024	0	-24	-21	-21	N/A
6/30/2024	0	-28	-24	-23	N/A
3/31/2024	0	-31	-23	-22	N/A
12/31/2023	0	-29	-22	-21	N/A
9/30/2023	0	-21	-18	-18	N/A
6/30/2023	0	-19	-17	-17	N/A
3/31/2023	0	-19	-17	-17	N/A
12/31/2022	0	-19	-16	-16	N/A
9/30/2022	0	-21	-16	-16	N/A
6/30/2022	0	-18	-15	-14	N/A
3/31/2022	0	-19	-14	-14	N/A
12/31/2021	0	-19	-15	-14	N/A
9/30/2021	0	-17	-12	-11	N/A
6/30/2021	0	-17	-11	-11	N/A
3/31/2021	0	-14	-11	-10	N/A
12/31/2020	0	-14	-11	-10	N/A
9/30/2020	0	-12	-10	-10	N/A
6/30/2020	0	-11	-10	-9	N/A
3/31/2020	0	-10	-11	-11	N/A
12/31/2019	0	-9	-9	-9	N/A
9/30/2019	0	-10	-9	-9	N/A
6/30/2019	0	-10	-10	-10	N/A
3/31/2019	0	-10	-10	-10	N/A
12/31/2018	0	-10	-11	-11	N/A
9/30/2018	0	-10	-9	-9	N/A
6/30/2018	0	-8	N/A	-8	N/A
3/31/2018	0	-8	N/A	-7	N/A
12/31/2017	0	-8	N/A	-8	N/A
9/30/2017	0	-7	N/A	-9	N/A
6/30/2017	0	-9	N/A	-10	N/A
3/31/2017	0	-8	N/A	-9	N/A
12/31/2016	0	-8	N/A	-7	N/A
9/30/2016	0	-9	N/A	-9	N/A
6/30/2016	0	-10	N/A	-9	N/A
3/31/2016	0	-14	N/A	-13	N/A
12/31/2015	0	-15	N/A	-16	N/A
9/30/2015	0	-17	N/A	-17	N/A
6/30/2015	0	-17	N/A	-17	N/A
3/31/2015	0	-17	N/A	-15	N/A
12/31/2014	0	-17	N/A	-14	N/A
9/30/2014	0	-16	N/A	-13	N/A
6/30/2014	0	-17	N/A	-13	N/A
3/31/2014	0	-16	N/A	-14	N/A
12/31/2013	0	-16	N/A	-17	N/A

アナリストによる今後の成長予測

収入対貯蓄率: HXB2今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: HXB2今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: HXB2今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: HXB2の収益 ( 74.5% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: HXB2の収益 ( 74.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HXB2の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

AIM ImmunoTech 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings released: US$0.064 loss per share (vs US$0.16 loss in 3Q 2023)

Kellner Group Urges Immediate Change at AIM Immunotech Inc

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Ted D. Kellner Sends a Notice to AIM ImmunoTech

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

New major risk - Revenue and earnings growth

New major risk - Financial position

Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023)

Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board

AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

New major risk - Financial position

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023)

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.60 loss per share (vs US$0.41 loss in FY 2022)

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.13 loss in 3Q 2022)

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2022)

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.12 loss in 2Q 2021)

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data

AIM ImmunoTech Inc. Provides Update on Ampligen Long COVID Development Program

First quarter 2022 earnings released: US$0.08 loss per share (vs US$0.078 loss in 1Q 2021)

Insufficient new directors

AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Announces Positive Data from Phase 1 Study Evaluating Ampligen

Full year 2021 earnings released: US$0.40 loss per share (vs US$0.45 loss in FY 2020)

AIM ImmunoTech Inc. Announces Executive Changes

AIM ImmunoTech Inc. Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer

Third quarter 2021 earnings released: US$0.08 loss per share (vs US$0.085 loss in 3Q 2020)

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

AIM Immunotech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-Covid-19 Cognitive Dysfunction

AIM ImmunoTech Inc. Provides Status Update on its Pending Phase 2A Human Challenge Trial Using its Drug Ampligen

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 2Q 2020)

AIM ImmunoTech Inc.(NYSEAM:AIM) dropped from Russell Microcap Growth Index